250 related articles for article (PubMed ID: 16236107)
1. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
2. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
3. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA
Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
[TBL] [Abstract][Full Text] [Related]
4. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
[TBL] [Abstract][Full Text] [Related]
5. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and in vivo properties of high purity factor IX concentrates.
Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
[TBL] [Abstract][Full Text] [Related]
7. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
[TBL] [Abstract][Full Text] [Related]
8. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
Hampton KK; Preston FE; Lowe GD; Walker ID; Sampson B
Br J Haematol; 1993 Jun; 84(2):279-84. PubMed ID: 8398831
[TBL] [Abstract][Full Text] [Related]
9. Influence of long term oral anticoagulants upon prothrombin fragment 1 + 2, thrombin-antithrombin III complex and D-Dimer levels in patients affected by proximal deep vein thrombosis.
Elias A; Bonfils S; Daoud-Elias M; Gauthier B; Sié P; Boccalon H; Boneu B
Thromb Haemost; 1993 Apr; 69(4):302-5. PubMed ID: 8497840
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1998 Mar; 79(3):509-10. PubMed ID: 9531030
[TBL] [Abstract][Full Text] [Related]
11. Coagulation and fibrinolytic markers in a two-month follow-up of coronary bypass surgery.
Parolari A; Colli S; Mussoni L; Eligini S; Naliato M; Wang X; Gandini S; Tremoli E; Biglioli P; Alamanni F
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):336-43. PubMed ID: 12579103
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
[TBL] [Abstract][Full Text] [Related]
13. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years.
Cadroy Y; Pierrejean D; Fontan B; Sié P; Boneu B
Nouv Rev Fr Hematol (1978); 1992; 34(1):43-6. PubMed ID: 1523099
[TBL] [Abstract][Full Text] [Related]
14. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
[TBL] [Abstract][Full Text] [Related]
15. Assessment of potential thrombogenicity of coagulation factor IX concentrates in an in vitro model of human thrombogenesis.
Galan AM; Reverter JC; Bozzo J; Hernandez MR; Escolar G; Aznar-Salatti J
Thromb Res; 1999 Dec; 96(5):383-9. PubMed ID: 10605953
[TBL] [Abstract][Full Text] [Related]
16. TAT, F1 + 2, and D-dimer levels in patients after coronary angiography with nonionic or ionic contrast media or after cardiac catheterization.
Biancardi M; Cimminiello C; Toschi V; Schiavina G; Regalia F; Casolo F; Bonfardeci G
Semin Thromb Hemost; 1996; 22 Suppl 1():61-5. PubMed ID: 8807731
[TBL] [Abstract][Full Text] [Related]
17. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
[TBL] [Abstract][Full Text] [Related]
18. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
19. [Quality control of prothrombin complex preparations: in vivo and in vitro findings].
Köhler M; Habauer G; Miyashita C; Braun B; Mörsdorf S; Pindur G; Heiden M; Rose S; Ernert P
Beitr Infusionsther; 1990; 26():186-9. PubMed ID: 1703826
[TBL] [Abstract][Full Text] [Related]
20. High sensitivity detection of activated factor IX: application to the analysis of different therapeutical factor IX concentrates and prothrombin complexes.
Kusch M; Seitz R; König H
Thromb Haemost; 1998 Apr; 79(4):778-83. PubMed ID: 9569192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
